The company said it was “pleased with
The medical imaging company issues solid guidance for 2025.
GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.
Get a deeper insight into the potential performance of GE HealthCare (GEHC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
GE HealthCare invests $138M to expand its Cork facility to enhance manufacturing capacity for life-saving imaging contrast media and strengthen its global supply chain.
GE HealthCare launches the enhanced Voluson Expert Series to advance women's health with faster, more precise imaging for improved care in obstetrics and gynecology.
GE HealthCare Technologies, spun off from General Electric in 2023, has shown significant stock growth, outperforming the S&P 500 by a wide margin. Despite mixed financial performance, the company remains undervalued compared to competitors, with potential for further growth in a large, expanding market. Management's optimistic guidance for 2024 and beyond, coupled with strategic investments and partnerships, supports continued revenue and profit growth.
GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.